CSL (ASX:CSL) Secures NICE Approval For Sparsentan Use In NHS England
We've spotted 1 possible red flag for CSL you should be aware of.
The latest GPUs need a type of rare earth metal called Dysprosium and there are only 24 companies in the world exploring or producing it. Find the list for free.
The recent developments regarding CSL's approval for sparsentan, a treatment recommended by the National Institute for Health and Care Excellence, may enhance the company's market position, potentially fueling revenue growth. Over the past three years, however, CSL's total return, inclusive of share price changes and dividends, recorded a decline of 4.64%. This contrasts against a broader 1-year underperformance both relative to the Australian market's 4.9% increase and the Australian Biotechs industry's -9.4% decrease, highlighting a need to bridge the performance gap with new advancements.
Looking forward, the impact of these medical endorsements might influence CSL's revenue and earnings forecasts positively, with anticipated expansion in the HAE and vaccine sectors playing a crucial role. Despite the current share price of A$251.13 being lower than the consensus analyst price target of A$311.94, suggesting a potential upswing, the market's fluctuations must be considered in investment evaluations. As CSL continues to hone operational efficiencies and product rollouts, assessing these factors against earnings projections will be vital in understanding its long-term trajectory.
According our valuation report, there's an indication that CSL's share price might be on the cheaper side.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include ASX:CSL.
This article was originally published by Simply Wall St.
Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@simplywallst.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
The three-year loss for CVS Health (NYSE:CVS) shareholders likely driven by its shrinking earnings
CVS Health Corporation (NYSE:CVS) shareholders should be happy to see the share price up 11% in the last month. But that doesn't change the fact that the returns over the last three years have been less than pleasing. After all, the share price is down 34% in the last three years, significantly under-performing the market. Although the past week has been more reassuring for shareholders, they're still in the red over the last three years, so let's see if the underlying business has been responsible for the decline. AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early. While the efficient markets hypothesis continues to be taught by some, it has been proven that markets are over-reactive dynamic systems, and investors are not always rational. One imperfect but simple way to consider how the market perception of a company has shifted is to compare the change in the earnings per share (EPS) with the share price movement. CVS Health saw its EPS decline at a compound rate of 17% per year, over the last three years. This fall in the EPS is worse than the 13% compound annual share price fall. So, despite the prior disappointment, shareholders must have some confidence the situation will improve, longer term. The graphic below depicts how EPS has changed over time (unveil the exact values by clicking on the image). It's good to see that there was some significant insider buying in the last three months. That's a positive. That said, we think earnings and revenue growth trends are even more important factors to consider. It might be well worthwhile taking a look at our free report on CVS Health's earnings, revenue and cash flow. What About Dividends? When looking at investment returns, it is important to consider the difference between total shareholder return (TSR) and share price return. The TSR is a return calculation that accounts for the value of cash dividends (assuming that any dividend received was reinvested) and the calculated value of any discounted capital raisings and spin-offs. It's fair to say that the TSR gives a more complete picture for stocks that pay a dividend. We note that for CVS Health the TSR over the last 3 years was -26%, which is better than the share price return mentioned above. This is largely a result of its dividend payments! A Different Perspective It's good to see that CVS Health has rewarded shareholders with a total shareholder return of 23% in the last twelve months. And that does include the dividend. Since the one-year TSR is better than the five-year TSR (the latter coming in at 5% per year), it would seem that the stock's performance has improved in recent times. In the best case scenario, this may hint at some real business momentum, implying that now could be a great time to delve deeper. I find it very interesting to look at share price over the long term as a proxy for business performance. But to truly gain insight, we need to consider other information, too. To that end, you should learn about the 3 warning signs we've spotted with CVS Health (including 1 which is a bit unpleasant) . If you like to buy stocks alongside management, then you might just love this free list of companies. (Hint: most of them are flying under the radar). Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on American exchanges. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
an hour ago
- Yahoo
Defense Stocks Just Got Even More Expensive
Key Points For the first two decades of the 21st century, defense stocks sold for an average of 1.4x sales. Today, these same defense stocks cost twice as much. The defense sector is booming, yes. But the risk is also rising. These 10 stocks could mint the next wave of millionaires › For more than a year now, I've been warning investors that defense stocks cost too much. At first, that warning seemed prescient, when shares of almost all of America's leading publicly traded defense companies declined within months of my sounding the alarm. Fast forward nearly a year, and things have gotten both better... and worse. The better: Defense stock prices bounced back (which should make current shareholders happy). The worse: As of today, almost all defense stocks look more overpriced than ever before. For anyone looking to buy new shares of defense stocks, this is bad news. What history says about defense stocks How do I come to these conclusions? By looking at the data. Over the 10-year period running from 2004 to 2013, over the 10 years running from 2014 to 2023, and over the 20-year period running from 2004 to 2023, I've calculated the average enterprise value-to-sales ratios (EV/S) for each of 10 major U.S. defense companies, using data from S&P Global Market Intelligence. (As a reminder, EV/S ratios are similar to price-to-sales ratios, except that EV/S adjusts market capitalizations to factor in net cash on the balance sheet -- or, more commonly, net debt). As you'll see below, these data show that defense companies early in the 21st century cost about 1x their annual sales, but that prices have been climbing steadily for the past decade. Averaging out the numbers, for the past 20 years defense stocks have cost about 40% more than their annual sales -- and this is the number I'm tentatively assuming to be the new "fair value" for defense stocks. Average enterprise value-to-sales ratio (EV/S) from: 2004-2013 2014-2023 2003-2023 Boeing (NYSE: BA) 0.89 1.83 1.36 General Dynamics (NYSE: GD) 1.04 1.68 1.36 Huntington Ingalls (NYSE: HII) 0.51* 1.14 0.64* Kratos Defense & Security Solutions (NASDAQ: KTOS) 0.97 2.21 1.59 Leidos Holdings (NYSE: LDOS) 1.5** 2.21 1.34** L3Harris Technologies (NYSE: LHX) 1.44 2.84 2.14 Lockheed Martin (NYSE: LMT) 0.81 1.78 1.30 Northrop Grumman (NYSE: NOC) 0.74 1.94 1.34 RTX Corp (NYSE: RTX) 1.42 2.07 1.74 Textron (NYSE: TXT) 1.31 1.17 1.24 Average 1.06 1.89 1.40 Data source: S&P Global Market Intelligence. * Huntington Ingalls data begins in 2011, the year when Northrop Grumman spun off Huntington Ingalls as a separate company. ** Leidos data begins in 2006, the year of its IPO. Data on its average enterprise value-to-sales ratio for 2014 is missing because the company changed its fiscal year in 2015, skewing the data somewhat. Now we compare these 20-year-average numbers to what the stocks cost today. (To make it easier for readers to quality-check my numbers, I provide both EV/S, and more commonly available P/S ratios). EV/S today Price-to-sales ratio today Boeing 2.74 2.21 General Dynamics 1.86 1.71 Huntington Ingalls 1.13 0.91 Kratos Defense & Security Solutions 9.20 8.87 Leidos Holdings 1.62 1.38 L3Harris Technologies 2.91 2.40 Lockheed Martin 1.69 1.42 Northrop Grumman 2.43 2.08 RTX Corp 2.95 2.51 Textron 1.16 1.03 Average 2.77 2.45 Data source: Yahoo! Finance. What this means for defense stock investors So what has changed since the last time we checked in on the defense stocks, three months ago? Basically, every single one of these stocks, with the sole exception of Lockheed Martin, has gotten more expensive. Lockheed, if you recall, suffered a steep sell-off after reporting "a significant profit miss" last month caused by a near-$1 billion charge on "a classified aerospace project," and it still hasn't fully recovered from that misstep. But all the others have. Again, this probably sounds like good news for investors who own defense stocks. But these stretched valuations bring with them a significant risk of future steep declines, for both existing and new buyers. The average EV/S ratio of this group, 2.77, means that defense stocks as a whole currently cost nearly twice what has historically been their fair value. Will this decline happen tomorrow? Probably not. In fact, with military tensions continuing to rise in the South China Sea and elsewhere, active conflict persisting in the Middle East, and Europe still embroiled in its biggest land conflict since World War II, investors may keep betting on military stocks for quite some time. But with valuations as extreme as what we see today, I simply don't see much reason to expect defense stocks to move higher. On the contrary, if I were to bet on it, my hunch is that over the next decade, defense stocks will underperform the S&P 500 by a significant margin. Don't miss this second chance at a potentially lucrative opportunity Ever feel like you missed the boat in buying the most successful stocks? Then you'll want to hear this. On rare occasions, our expert team of analysts issues a 'Double Down' stock recommendation for companies that they think are about to pop. If you're worried you've already missed your chance to invest, now is the best time to buy before it's too late. And the numbers speak for themselves: Nvidia: if you invested $1,000 when we doubled down in 2009, you'd have $467,985!* Apple: if you invested $1,000 when we doubled down in 2008, you'd have $44,015!* Netflix: if you invested $1,000 when we doubled down in 2004, you'd have $668,155!* Right now, we're issuing 'Double Down' alerts for three incredible companies, available when you join , and there may not be another chance like this anytime soon.*Stock Advisor returns as of August 13, 2025 Rich Smith has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends L3Harris Technologies. The Motley Fool recommends Lockheed Martin, RTX, and Textron. The Motley Fool has a disclosure policy. Defense Stocks Just Got Even More Expensive was originally published by The Motley Fool
Yahoo
2 hours ago
- Yahoo
Metals Exploration plc (LON:MTL) has caught the attention of institutional investors who hold a sizeable 39% stake
Key Insights Institutions' substantial holdings in Metals Exploration implies that they have significant influence over the company's share price A total of 3 investors have a majority stake in the company with 50% ownership Insiders have bought recently We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free. Every investor in Metals Exploration plc (LON:MTL) should be aware of the most powerful shareholder groups. And the group that holds the biggest piece of the pie are institutions with 39% ownership. That is, the group stands to benefit the most if the stock rises (or lose the most if there is a downturn). Given the vast amount of money and research capacities at their disposal, institutional ownership tends to carry a lot of weight, especially with individual investors. As a result, a sizeable amount of institutional money invested in a firm is generally viewed as a positive attribute. Let's take a closer look to see what the different types of shareholders can tell us about Metals Exploration. View our latest analysis for Metals Exploration What Does The Institutional Ownership Tell Us About Metals Exploration? Institutional investors commonly compare their own returns to the returns of a commonly followed index. So they generally do consider buying larger companies that are included in the relevant benchmark index. We can see that Metals Exploration does have institutional investors; and they hold a good portion of the company's stock. This implies the analysts working for those institutions have looked at the stock and they like it. But just like anyone else, they could be wrong. It is not uncommon to see a big share price drop if two large institutional investors try to sell out of a stock at the same time. So it is worth checking the past earnings trajectory of Metals Exploration, (below). Of course, keep in mind that there are other factors to consider, too. Metals Exploration is not owned by hedge funds. Looking at our data, we can see that the largest shareholder is Candy Ventures S.à R.L. with 22% of shares outstanding. Meanwhile, the second and third largest shareholders, hold 20% and 7.6%, of the shares outstanding, respectively. Furthermore, CEO Darren Bowden is the owner of 0.7% of the company's shares. After doing some more digging, we found that the top 3 shareholders collectively control more than half of the company's shares, implying that they have considerable power to influence the company's decisions. Researching institutional ownership is a good way to gauge and filter a stock's expected performance. The same can be achieved by studying analyst sentiments. There is a little analyst coverage of the stock, but not much. So there is room for it to gain more coverage. Insider Ownership Of Metals Exploration The definition of an insider can differ slightly between different countries, but members of the board of directors always count. Company management run the business, but the CEO will answer to the board, even if he or she is a member of it. Most consider insider ownership a positive because it can indicate the board is well aligned with other shareholders. However, on some occasions too much power is concentrated within this group. Shareholders would probably be interested to learn that insiders own shares in Metals Exploration plc. In their own names, insiders own UK£19m worth of stock in the UK£404m company. This shows at least some alignment. You can click here to see if those insiders have been buying or selling. General Public Ownership The general public-- including retail investors -- own 13% stake in the company, and hence can't easily be ignored. This size of ownership, while considerable, may not be enough to change company policy if the decision is not in sync with other large shareholders. Private Equity Ownership Private equity firms hold a 22% stake in Metals Exploration. This suggests they can be influential in key policy decisions. Sometimes we see private equity stick around for the long term, but generally speaking they have a shorter investment horizon and -- as the name suggests -- don't invest in public companies much. After some time they may look to sell and redeploy capital elsewhere. Private Company Ownership We can see that Private Companies own 21%, of the shares on issue. Private companies may be related parties. Sometimes insiders have an interest in a public company through a holding in a private company, rather than in their own capacity as an individual. While it's hard to draw any broad stroke conclusions, it is worth noting as an area for further research. Next Steps: It's always worth thinking about the different groups who own shares in a company. But to understand Metals Exploration better, we need to consider many other factors. For instance, we've identified 3 warning signs for Metals Exploration (1 is a bit concerning) that you should be aware of. If you are like me, you may want to think about whether this company will grow or shrink. Luckily, you can check this free report showing analyst forecasts for its future. NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
